| scholarly article | Q13442814 |
| P50 | author | Eugene K. Cha | Q37839556 |
| Jonathan E Rosenberg | Q42862184 | ||
| Nikolaus Schultz | Q42862190 | ||
| Hikmat Al-Ahmadie | Q42862200 | ||
| Bernard H Bochner | Q42862211 | ||
| Gopa Iyer | Q87340030 | ||
| Dean F Bajorin | Q88172016 | ||
| Aditya Bagrodia | Q89894166 | ||
| Irina Ostrovnaya | Q90067884 | ||
| David B Solit | Q90267706 | ||
| Guido Dalbagni | Q90857016 | ||
| Eugene J Pietzak | Q124155234 | ||
| P2093 | author name string | Qiang Li | |
| Michael F Berger | |||
| Sumit Isharwal | |||
| Ahmet Zehir | |||
| Priscilla Baez | |||
| Esther N Drill | |||
| P2860 | cites work | ARID1A mutations in endometriosis-associated ovarian carcinomas | Q24610484 |
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers | Q28257103 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden | Q33568623 | ||
| Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review | Q33929786 | ||
| Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma | Q34549516 | ||
| ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. | Q34708383 | ||
| Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder | Q35034441 | ||
| p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Guérin: a meta-analysis | Q35572365 | ||
| Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology | Q35584856 | ||
| Mutational inactivation of STAG2 causes aneuploidy in human cancer | Q36029045 | ||
| Genomic Characterization of Upper Tract Urothelial Carcinoma | Q36362571 | ||
| DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. | Q36910861 | ||
| Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States | Q37093851 | ||
| Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels | Q37130135 | ||
| Recurrence of high-risk bladder cancer: a population-based analysis. | Q37171429 | ||
| Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. | Q37341453 | ||
| Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes | Q37649062 | ||
| The mechanism of action of BCG therapy for bladder cancer--a current perspective | Q38184849 | ||
| Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity | Q38297729 | ||
| Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome | Q39098321 | ||
| Oncogenic FGFR3 gene fusions in bladder cancer | Q39240290 | ||
| The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing | Q40536461 | ||
| Genomic characterization of response to chemoradiation in urothelial bladder cancer | Q44338887 | ||
| Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine | Q44413803 | ||
| Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation | Q45823928 | ||
| Mutational context and diverse clonal development in early and late bladder cancer. | Q53144252 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| bladder cancer | Q504775 | ||
| P577 | publication date | 2017-06-02 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets |
| Q92133160 | A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma |
| Q90087089 | A six-gene prognostic model predicts overall survival in bladder cancer patients |
| Q57167864 | ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response? |
| Q103836778 | Advances in bladder cancer biology and therapy |
| Q64927304 | Advances in risk stratification of bladder cancer to guide personalized medicine. |
| Q91900128 | Bioinformatics Analysis Identified Key Molecular Changes in Bladder Cancer Development and Recurrence |
| Q92663356 | Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review |
| Q92487363 | Biomarkers for platinum sensitivity in bladder cancer: are we there yet? |
| Q92128606 | Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches |
| Q92908635 | Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer |
| Q89989625 | Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target |
| Q58115640 | Fibroblast growth factor receptors as treatment targets in clinical oncology |
| Q93044588 | Functional genetic variant of WW domain containing oxidoreductase gene associated with urothelial cell carcinoma clinicopathologic characteristics and long-term survival |
| Q91671552 | Functional network analysis of gene-phenotype connectivity based on pioglitazone |
| Q91698505 | GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer |
| Q91968395 | Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status |
| Q57045992 | Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy |
| Q89510134 | Genomic Landscape of Young-Onset Bladder Cancer and Its Prognostic Implications on Adult Bladder Cancer |
| Q47404654 | Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency |
| Q91401487 | Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer |
| Q92240245 | High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer |
| Q57291360 | Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma |
| Q92448069 | Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer |
| Q92059098 | Impact of RAGE polymorphisms on urothelial cell carcinoma clinicopathologic characteristics and long-term survival |
| Q91557791 | Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma |
| Q89463356 | Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities |
| Q58704141 | Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring |
| Q58113597 | Management of High-grade T1 Urothelial Carcinoma |
| Q58613925 | Molecular Characterization of Bladder Cancer |
| Q90690150 | Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma |
| Q61842764 | Mutational landscape of non-muscle-invasive bladder cancer |
| Q49206807 | Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor |
| Q49463616 | Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. |
| Q57466513 | P3H4 is correlated with clinicopathological features and prognosis in bladder cancer |
| Q64262696 | Prediction tools in non-muscle invasive bladder cancer |
| Q91401482 | Predictors of Response to Intravesical Therapy |
| Q91401470 | Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer |
| Q90469821 | SIU-ICUD consultation on bladder cancer: basic science |
| Q63984741 | Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer |
| Q90463014 | Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread |
| Q57464869 | T1 bladder cancer: current considerations for diagnosis and management |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q52724470 | The evolution of bladder cancer genomics: What have we learned and how can we use it? |
| Q50072573 | Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation |
| Q52602391 | Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. |
| Q55427566 | Unmasking molecular profiles of bladder cancer. |
| Q88334763 | Unravelling disparate roles of NOTCH in bladder cancer |
| Q89817680 | Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study |
| Q92837837 | YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo-/radio-resistance by suppressing caspase-mediated apoptosis |
| Q97067553 | [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC] |
Search more.